tiprankstipranks

Argenx price target raised to $497 from $465 at Jefferies

Jefferies analyst Akash Tewari raised the firm’s price target on Argenx to $497 from $465 and keeps a Buy rating on the shares. The company’s efgartigimod Phase 2 in LC-POTS is an under-the-radar catalyst, and the firm believes there is reasonable clinical rationale with a number of cases providing early PoC, the analyst tells investors in a research note. Jefferies thinks Long COVID-POTS represents a significant market opportunity.

Published first on TheFly

See Insiders’ Hot Stocks on TipRanks >>

Read More on ARGX:

Disclaimer & DisclosureReport an Issue